+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Neoantigen Cancer Vaccine Market By Product, By Neoantigen Type, By Route of Administration, By Cell, By Technology, By Delivery Mechanism, By Application, By Region, Competition, Forecast & Opportunities, 2025

  • ID: 5031368
  • Report
  • May 2020
  • Region: Global
  • 111 pages
  • TechSci Research
UP TO OFF
until Jul 31st 2020
Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now
The Global Neoantigen Cancer Vaccine Market is Projected to Grow at a CAGR of Close to 35% During the Forecast Period.

FEATURED COMPANIES

  • Advaxis
  • BioNTech
  • Genocea Biosciences
  • ISA Pharmaceutical
  • Moderna
  • Pfizer
  • MORE
The Global Neoantigen Cancer Vaccine Market is projected to grow at a CAGR of close to 35% during the forecast period. The key factor responsible for the growth of the neoantigen cancer vaccine market is rapid innovations in technology as well as infrastructural developments in the healthcare sector. Additionally, growing investments by the governing bodies and healthcare providers is another major factor that is anticipated to bode well for the growth of the neoantigen cancer vaccine market across the globe in the coming years. Moreover, rising cases of cancers is further anticipated to bolster the market growth through 2025.

The Global Neoantigen Cancer Vaccine Market is segmented based on product, neoantigen type, route of administration, cell, technology, delivery mechanism, application, region and company. Based on route of administration, the market can be segmented into intravenous, intramuscular, transdermal and others. Out of which, the intravenous segment dominated the market until 2019 and is further anticipated to be the fastest-growing application segment of the neoantigen cancer vaccine market during the forecast period as well. This growth can be accredited to quick response as well as the to the fact that drug dosage can be controlled easily. Along with that, intramuscular injections can be used rather than intravenous because some drugs cause irritation to veins when injected intravenously. This is expected to result in high growth of intramuscular route of the administration segment over the coming years.

Major players operating in the Global Neoantigen Cancer Vaccine Market include Avidea Technologies, Agenus, Roche, Nouscom, Merck, Pfizer, Advaxis, Medigene, Genocea Biosciences, Gritstone Oncology, Gilead Sciences, Eli Lilly, Novogene, Moderna, BioNTech, Ziopharm, ISA Pharmaceutical, Vaccibody, Brightpath Bio, Vaximm, etc. The companies operating in the market across the globe are focussing more towards expanding their share in the market.

Years considered for this report:
  • Historical Years: 2015-2018
  • Base Year: 2019
  • Estimated Year: 2020
  • Forecast Period: 2021–2025
Objective of the Study:
  • To analyse and forecast the market size of the Global Neoantigen Cancer Vaccine Market.
  • To classify and forecast the Global Neoantigen Cancer Vaccine Market based on product, neoantigen type, route of administration, cell, technology, delivery mechanism, application, company and regional distribution.
  • To identify drivers and challenges for the Global Neoantigen Cancer Vaccine Market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in the Global Neoantigen Cancer Vaccine Market.
  • To conduct pricing analysis for the Global Neoantigen Cancer Vaccine Market.
  • To identify and analyse the profile of leading players operating in the Global Neoantigen Cancer Vaccine Market.
The author performed both primary as well as exhaustive secondary research for this study. Initially, researchers sourced a list of manufacturers across the globe. Subsequently, researchers conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, researchers could include the manufacturers which could not be identified due to the limitations of secondary research. The author analyzed the new products, distribution channels and presence of all major players across the globe.

The author calculated the market size of the Global Neoantigen Cancer Vaccine Market by using a bottom-up approach, wherein the data for various end-user segments was recorded and forecast for the future years. The author sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied.

Key Target Audience:
  • Neoantigen cancer vaccine manufacturers, suppliers, distributors and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to neoantigen cancer vaccine
  • Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, partners, end-users, etc., besides allowing them in strategizing investments and capitalizing on the market opportunities.

Report Scope:
In this report, the Global Neoantigen Cancer Vaccine Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Market, By Product:
  • Personalized neo-antigen vaccine
  • Off-the shell neoantigen vaccine
Market, By Neoantigen Type:
  • Nucleic acid
  • Dendritic cell
  • Tumor cell
  • Synthetic Long Peptide
Market, By Route of Administration:
  • Intravenous
  • Intramuscular
  • Transdermal
  • Others
Market, By Cell:
  • Autologous
  • Allogenic
Market, By Technology:
  • Whole Genome Sequencing
  • RNA Sequencing
  • HLA Typing
Market, By Delivery Mechanism:
  • Gene gun
  • Electroporation
  • Liposomes
  • Virosomes
  • Others
Market, By Application:
  • Melanoma
  • Brain cancer
  • Gastrointestinal
  • Lung
  • Others
Market, By Region:
  • North America
  • United States
  • Mexico
  • Canada
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Singapore
  • Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • South America
  • Brazil
  • Argentina
  • Colombia
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Neoantigen Cancer Vaccine Market.

Available Customizations:
With the given market data, the author offers customizations according to a client’s specific needs.

This report is 80% complete and can be delivered within three working days post order confirmation and will include the latest impact analysis of Covid-19 in 2020 and forecast. If you buy the ‘Multi-user’ License of this report before June 2020, you will get a free update in form of market data excel sheet within 3 to 6 months of your purchase on request.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Advaxis
  • BioNTech
  • Genocea Biosciences
  • ISA Pharmaceutical
  • Moderna
  • Pfizer
  • MORE
1. Product Overview

2. Research Methodology

3. Executive Summary

4. Global Neoantigen Cancer Vaccine Market Outlook
4.1. Market Size & Forecast
4.1.1. By Value & Volume
4.2. Market Share & Forecast
4.2.1. By Product (Personalized neo-antigen vaccine, Off-the shell neoantigen vaccine)
4.2.2. By Neoantigen Type (Nucleic acid, Dendritic cell, Tumor cell and Synthetic long peptide (SLP))
4.2.3. By Route of Administration (Intravenous, Intramuscular, Transdermal, Others)
4.2.4. By Cell (Autologous, Allogenic)
4.2.5. By Technology (Whole Genome Sequencing, RNA Sequencing, HLA Typing)
4.2.6. By Delivery Mechanism (Gene gun, Electroporation, Liposomes, Virosomes and Others)
4.2.7. By Application (Melanoma, Brain cancer, Gastrointestinal, Lung and Others)
4.2.8. By Company (2019)
4.2.9. By Region
4.3. Market Attractiveness Index

5. Asia-Pacific Neoantigen Cancer Vaccine Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value & Volume
5.2. Market Share & Forecast
5.2.1. By Product
5.2.2. By Neoantigen Type
5.2.3. By Route of Administration
5.2.4. By Cell
5.2.5. By Technology
5.2.6. By Application
5.2.7. By Country
5.3. Market Attractiveness Index
5.4. Asia-Pacific: Country Analysis
5.4.1. China Neoantigen Cancer Vaccine Market Outlook
5.4.1.1. Market Size & Forecast
5.4.1.1.1. By Value
5.4.1.2. Market Share & Forecast
5.4.1.2.1. By Product
5.4.1.2.2. By Neoantigen Type
5.4.1.2.3. By Route of Administration
5.4.1.2.4. By Cell
5.4.1.2.5. By Technology
5.4.1.2.6. By Application
5.4.2. India Neoantigen Cancer Vaccine Market Outlook
5.4.2.1. Market Size & Forecast
5.4.2.1.1. By Value
5.4.2.2. Market Share & Forecast
5.4.2.2.1. By Product
5.4.2.2.2. By Neoantigen Type
5.4.2.2.3. By Route of Administration
5.4.2.2.4. By Cell
5.4.2.2.5. By Technology
5.4.2.2.6. By Application
5.4.3. Japan Neoantigen Cancer Vaccine Market Outlook
5.4.3.1. Market Size & Forecast
5.4.3.1.1. By Value
5.4.3.2. Market Share & Forecast
5.4.3.2.1. By Product
5.4.3.2.2. By Neoantigen Type
5.4.3.2.3. By Route of Administration
5.4.3.2.4. By Cell
5.4.3.2.5. By Technology
5.4.3.2.6. By Application
5.4.4. South Korea Neoantigen Cancer Vaccine Market Outlook
5.4.4.1. Market Size & Forecast
5.4.4.1.1. By Value
5.4.4.2. Market Share & Forecast
5.4.4.2.1. By Product
5.4.4.2.2. By Neoantigen Type
5.4.4.2.3. By Route of Administration
5.4.4.2.4. By Cell
5.4.4.2.5. By Technology
5.4.4.2.6. By Application
5.4.5. Singapore Neoantigen Cancer Vaccine Market Outlook
5.4.5.1. Market Size & Forecast
5.4.5.1.1. By Value
5.4.5.2. Market Share & Forecast
5.4.5.2.1. By Product
5.4.5.2.2. By Neoantigen Type
5.4.5.2.3. By Route of Administration
5.4.5.2.4. By Cell
5.4.5.2.5. By Technology
5.4.5.2.6. By Application
5.4.6. Australia Neoantigen Cancer Vaccine Market Outlook
5.4.6.1. Market Size & Forecast
5.4.6.1.1. By Value
5.4.6.2. Market Share & Forecast
5.4.6.2.1. By Product
5.4.6.2.2. By Neoantigen Type
5.4.6.2.3. By Route of Administration
5.4.6.2.4. By Cell
5.4.6.2.5. By Technology
5.4.6.2.6. By Application

6. Europe Neoantigen Cancer Vaccine Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value & Volume
6.2. Market Share & Forecast
6.2.1. By Product
6.2.2. By Neoantigen Type
6.2.3. By Route of Administration
6.2.4. By Cell
6.2.5. By Technology
6.2.6. By Application
6.2.7. By Country
6.3. Market Attractiveness Index
6.4. Europe: Country Analysis
6.4.1. France Neoantigen Cancer Vaccine Market Outlook
6.4.1.1. Market Size & Forecast
6.4.1.1.1. By Value
6.4.1.2. Market Share & Forecast
6.4.1.2.1. By Product
6.4.1.2.2. By Neoantigen Type
6.4.1.2.3. By Route of Administration
6.4.1.2.4. By Cell
6.4.1.2.5. By Technology
6.4.1.2.6. By Application
6.4.2. Germany Neoantigen Cancer Vaccine Market Outlook
6.4.2.1. Market Size & Forecast
6.4.2.1.1. By Value
6.4.2.2. Market Share & Forecast
6.4.2.2.1. By Product
6.4.2.2.2. By Neoantigen Type
6.4.2.2.3. By Route of Administration
6.4.2.2.4. By Cell
6.4.2.2.5. By Technology
6.4.2.2.6. By Application
6.4.3. United Kingdom Neoantigen Cancer Vaccine Market Outlook
6.4.3.1. Market Size & Forecast
6.4.3.1.1. By Value
6.4.3.2. Market Share & Forecast
6.4.3.2.1. By Product
6.4.3.2.2. By Neoantigen Type
6.4.3.2.3. By Route of Administration
6.4.3.2.4. By Cell
6.4.3.2.5. By Technology
6.4.3.2.6. By Application
6.4.4. Italy Neoantigen Cancer Vaccine Market Outlook
6.4.4.1. Market Size & Forecast
6.4.4.1.1. By Value
6.4.4.2. Market Share & Forecast
6.4.4.2.1. By Product
6.4.4.2.2. By Neoantigen Type
6.4.4.2.3. By Route of Administration
6.4.4.2.4. By Cell
6.4.4.2.5. By Technology
6.4.4.2.6. By Application
6.4.5. Spain Neoantigen Cancer Vaccine Market Outlook
6.4.5.1. Market Size & Forecast
6.4.5.1.1. By Value
6.4.5.2. Market Share & Forecast
6.4.5.2.1. By Product
6.4.5.2.2. By Neoantigen Type
6.4.5.2.3. By Route of Administration
6.4.5.2.4. By Cell
6.4.5.2.5. By Technology
6.4.5.2.6. By Application

7. North America Neoantigen Cancer Vaccine Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value & Volume
7.2. Market Share & Forecast
7.2.1. By Product
7.2.2. By Neoantigen Type
7.2.3. By Route of Administration
7.2.4. By Cell
7.2.5. By Technology
7.2.6. By Application
7.2.7. By Country
7.3. Market Attractiveness Index
7.4. North America: Country Analysis
7.4.1. United States Neoantigen Cancer Vaccine Market Outlook
7.4.1.1. Market Size & Forecast
7.4.1.1.1. By Value
7.4.1.2. Market Share & Forecast
7.4.1.2.1. By Product
7.4.1.2.2. By Neoantigen Type
7.4.1.2.3. By Route of Administration
7.4.1.2.4. By Cell
7.4.1.2.5. By Technology
7.4.1.2.6. By Application
7.4.2. Mexico Neoantigen Cancer Vaccine Market Outlook
7.4.2.1. Market Size & Forecast
7.4.2.1.1. By Value
7.4.2.2. Market Share & Forecast
7.4.2.2.1. By Product
7.4.2.2.2. By Neoantigen Type
7.4.2.2.3. By Route of Administration
7.4.2.2.4. By Cell
7.4.2.2.5. By Technology
7.4.2.2.6. By Application
7.4.3. Canada Neoantigen Cancer Vaccine Market Outlook
7.4.3.1. Market Size & Forecast
7.4.3.1.1. By Value
7.4.3.2. Market Share & Forecast
7.4.3.2.1. By Product
7.4.3.2.2. By Neoantigen Type
7.4.3.2.3. By Route of Administration
7.4.3.2.4. By Cell
7.4.3.2.5. By Technology
7.4.3.2.6. By Application

8. South America Neoantigen Cancer Vaccine Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value & Volume
8.2. Market Share & Forecast
8.2.1. By Product
8.2.2. By Neoantigen Type
8.2.3. By Route of Administration
8.2.4. By Cell
8.2.5. By Technology
8.2.6. By Application
8.2.7. By Country
8.3. Market Attractiveness Index
8.4. South America: Country Analysis
8.4.1. Brazil Neoantigen Cancer Vaccine Market Outlook
8.4.1.1. Market Size & Forecast
8.4.1.1.1. By Value
8.4.1.2. Market Share & Forecast
8.4.1.2.1. By Product
8.4.1.2.2. By Neoantigen Type
8.4.1.2.3. By Route of Administration
8.4.1.2.4. By Cell
8.4.1.2.5. By Technology
8.4.1.2.6. By Application
8.4.2. Argentina Neoantigen Cancer Vaccine Market Outlook
8.4.2.1. Market Size & Forecast
8.4.2.1.1. By Value
8.4.2.2. Market Share & Forecast
8.4.2.2.1. By Product
8.4.2.2.2. By Neoantigen Type
8.4.2.2.3. By Route of Administration
8.4.2.2.4. By Cell
8.4.2.2.5. By Technology
8.4.2.2.6. By Application
8.4.3. Colombia Neoantigen Cancer Vaccine Market Outlook
8.4.3.1. Market Size & Forecast
8.4.3.1.1. By Value
8.4.3.2. Market Share & Forecast
8.4.3.2.1. By Product
8.4.3.2.2. By Neoantigen Type
8.4.3.2.3. By Route of Administration
8.4.3.2.4. By Cell
8.4.3.2.5. By Technology
8.4.3.2.6. By Application

9. Middle East and Africa Neoantigen Cancer Vaccine Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value & Volume
9.2. Market Share & Forecast
9.2.1. By Product
9.2.2. By Neoantigen Type
9.2.3. By Route of Administration
9.2.4. By Cell
9.2.5. By Technology
9.2.6. By Application
9.2.7. By Country
9.3. Market Attractiveness Index
9.4. MEA: Country Analysis
9.4.1. South Africa Neoantigen Cancer Vaccine Market Outlook
9.4.1.1. Market Size & Forecast
9.4.1.1.1. By Value
9.4.1.2. Market Share & Forecast
9.4.1.2.1. By Product
9.4.1.2.2. By Neoantigen Type
9.4.1.2.3. By Route of Administration
9.4.1.2.4. By Cell
9.4.1.2.5. By Technology
9.4.1.2.6. By Application
9.4.2. Saudi Arabia Neoantigen Cancer Vaccine Market Outlook
9.4.2.1. Market Size & Forecast
9.4.2.1.1. By Value
9.4.2.2. Market Share & Forecast
9.4.2.2.1. By Product
9.4.2.2.2. By Neoantigen Type
9.4.2.2.3. By Route of Administration
9.4.2.2.4. By Cell
9.4.2.2.5. By Technology
9.4.2.2.6. By Application
9.4.3. UAE Neoantigen Cancer Vaccine Market Outlook
9.4.3.1. Market Size & Forecast
9.4.3.1.1. By Value
9.4.3.2. Market Share & Forecast
9.4.3.2.1. By Product
9.4.3.2.2. By Neoantigen Type
9.4.3.2.3. By Route of Administration
9.4.3.2.4. By Cell
9.4.3.2.5. By Technology
9.4.3.2.6. By Application

10. Market Dynamics
10.1. Drivers
10.2. Challenges

11. Market Trends & Developments

12. Competitive Landscape
12.1. Competition Outlook
12.2. Players Profiled (Leading Companies)
12.2.1. Avidea Technologies
12.2.2. Agenus
12.2.3. Roche
12.2.4. Nouscom
12.2.5. Merck
12.2.6. Pfizer
12.2.7. Advaxis
12.2.8. Medigene
12.2.9. Genocea Biosciences
12.2.10. Gritstone Oncology
12.2.11. Gilead Sciences
12.2.12. Eli Lilly
12.2.13. Novogene
12.2.14. Moderna
12.2.15. BioNTech
12.2.16. Ziopharm
12.2.17. ISA Pharmaceutical
12.2.18. Vaccibody
12.2.19. Brightpath Bio
12.2.20. Vaximm

13. Strategic Recommendations

14. About the author & Disclaimer
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Avidea Technologies
  • Agenus
  • Roche
  • Nouscom
  • Merck
  • Pfizer
  • Advaxis
  • Medigene
  • Genocea Biosciences
  • Gritstone Oncology
  • Gilead Sciences
  • Eli Lilly
  • Novogene
  • Moderna
  • BioNTech
  • Ziopharm
  • ISA Pharmaceutical
  • Vaccibody
  • Brightpath Bio
  • Vaximm
Note: Product cover images may vary from those shown
Adroll
adroll